Myeloproliferative neoplasm, unclassifiable
MONDO:0019452This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.
Also known as: CMPD, U, CMPD-U, MPN, U, MPN-U, chronic myeloproliferative disease, unclassifiable, chronic myeloproliferative disorder, unclassifiable, myeloproliferative neoplasm, unclassifiable, unclassifiable chronic myeloproliferative disease
3079 clinical trials for this condition and its sub-types, 11 tagged with Myeloproliferative neoplasm, unclassifiable itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloproliferative neoplasm, unclassifiable
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a targeted drug make stem cell transplants more effective for tough blood cancers?
Disease control OngoingThis early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy before and after a bone marrow transplant can help prevent cancer from coming back in people with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related blood…
Phase 1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Blood cancer patients' immune system may hold clues to severe COVID-19
Knowledge-focused OngoingThis study examines whether people with certain blood cancers (myeloproliferative neoplasms) have autoantibodies that block a key immune protein called type I interferon. These autoantibodies may increase the risk of severe COVID-19. Researchers will test blood samples from 219 p…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC